Feds scoop up a band of biotech insiders who allegedly bagged a windfall, and now criminal charges
Early last year, investors in Celator picked up a 72% premium when Jazz swooped in to buy the company and its lead drug for acute …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
